Summary of Contineum Therapeutics Conference Call Company Overview - Company: Contineum Therapeutics (NasdaqGS:CTNM) - Focus: Small molecule drug development in neuroscience, inflammation, and immunology, particularly targeting pulmonary fibrosis [3][4] Core Strategic Focus - Transitioned from a platform-based drug discovery model to a company with two clinical-stage assets: PIPE-791 and PIPE-307 [3] - PIPE-791 is a best-in-class inhibitor of the LPA1 receptor, with two key clinical trials planned for 2026 [3][4] - PIPE-307 is a first-in-class brain-penetrant M1 receptor inhibitor, partnered with Johnson & Johnson, currently in a Phase 2 study for major depressive disorder (MDD) [4][28] Clinical Trials and Data PIPE-791 - Clinical Trials: Three ongoing trials, including an exploratory study in chronic pain and a Phase 2 study in idiopathic pulmonary fibrosis (IPF) [3][4] - Differentiators: - Achieves 90% receptor occupancy at a low dose of 1 mg daily, compared to BMS's higher dose requirement [8][10] - No hypotension signal observed in studies, unlike BMS's compound [8][18] - Designed for convenience with a once-daily dosing regimen [10][27] - Phase 2 Study Design: 108 subjects, three arms (placebo and two doses), 26-week duration, allowing background therapy [11][12] PIPE-307 - Study Focus: MDD with a primary efficacy endpoint of change in MADRS on day five [29] - Partnership Economics: $50 million upfront from J&J, over $1 billion in milestones, and royalties starting in the low teens, potentially reaching 20% [35] Market Position and Competitive Dynamics - Contineum aims to position PIPE-791 as a backbone therapy for IPF, with potential for combination therapies [25][27] - The company believes it has a best-in-class approach, differentiating itself from competitors like BMS [25][27] Upcoming Catalysts - Key Data Events: - Results from the BMS Phase 3 trial expected in Q4 2026, which could validate the LPA1 target [20][57] - Readout from the MDD study (MOONLIGHT 1) anticipated in late summer or early fall [57] - Results from the chronic pain exploratory study, although not a primary investment thesis [37][57] Key Opinion Leader (KOL) Feedback - Positive feedback on the LPA1 mechanism, with enthusiasm for the once-daily dosing and tolerability profile [51][52] - Clinical validation from BMS's data is seen as a strong indicator of potential success for Contineum's programs [53] Financial Position - The company is well-funded through mid-2029, with no immediate financial obligations for PIPE-307 due to J&J's support [47] Conclusion - Contineum Therapeutics is positioned to leverage its clinical assets PIPE-791 and PIPE-307 in the competitive landscape of pulmonary fibrosis and major depressive disorder, with several key data readouts expected to drive investor interest and validate its strategic direction [53][57]
Contineum Therapeutics (NasdaqGS:CTNM) 2026 Conference Transcript